Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 8/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875130 | 0.84 | KLKB1 (0.47) | KLKB1GRM4NAMPTALDH1A1KMT2A | |
| SCHEMBL21875160 | 0.83 | KLKB1 (0.48) | KLKB1GRM4POLBNAMPTALDH1A1 | |
| SCHEMBL21875069 | 0.82 | NAMPT (0.48) | KLKB1GRM4NAMPT | |
| SCHEMBL21875171 | 0.82 | KLKB1 (0.49) | KLKB1GRM4POLBNAMPTALDH1A1 | |
| SCHEMBL21875153 | 0.81 | GRM4 (0.50) | KLKB1GRM4NAMPTALDH1A1KMT2A | |
| SCHEMBL21875076 | 0.81 | KCNJ1 (0.56) | KLKB1GRM4POLBALDH1A1 | |
| SCHEMBL21875121 | 0.81 | GRM4 (0.47) | KLKB1GRM4NAMPTALDH1A1KMT2A | |
| SCHEMBL21875079 | 0.81 | KLKB1 (0.48) | KLKB1GRM4POLBNAMPTALDH1A1 | |
| SCHEMBL21875135 | 0.81 | KLKB1 (0.48) | KLKB1GRM4NAMPTROCK2ALDH1A1 | |
| SCHEMBL21875080 | 0.81 | KLKB1 (0.48) | KLKB1GRM4NAMPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873891-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS | H. Lundbeck A/S (DK) | 2021-09-08 | — | — | EP | claimed |
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | claimed |
| EP-3873891-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS | H. Lundbeck A/S (DK) | 2021-09-08 | — | — | EP | disclosed |
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | KCNA3, KCNN3, KCNK3 | KLKB1 784/4885GRM4 1103/4885POLB 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.